MAPK3 and B-cell chronic lymphocytic leukemia: By binding to its receptor FGF-R3 [132], FGF-2 increases CLL cell survival through the activation of ERK1/2 and c-Src kinases, STAT3 phosphorylation, and activation of Mcl-1 and Bcl-2 (another major member of the pro-survival BCL-2 family) [2,68,96] (Table 1).